[{"orgOrder":0,"company":"Medigen Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medigen Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medigen Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Medigen Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Nivolumab","moa":"||Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nordic Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nordic Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nordic Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nordic Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tegafur","moa":"||RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"National Cancer Centre, Singapore","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tegafur","moa":"RNA | Thymidylate synthase | DNA","graph1":"Oncology","graph2":"Phase II","graph3":"National Cancer Centre, Singapore","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Centre, Singapore \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Centre, Singapore \/ Taiho Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals for Tegafur

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medigen Biotechnology

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Medigen Biotechnology

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 12, 2024

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          National Cancer Centre, Singapore

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          National Cancer Centre, Singapore

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 17, 2023

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Taiho Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : TS-1 is a combination of three pharmacological compounds: tegafur, an antimetabolite agent that, after absorption by the gastrointestinal tract, is converted into the anticancer agent fluorouracil (5-FU); gimeracil (5-chloro-2, 4-dihydroxypyridine, or CD...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 24, 2022

                          Lead Product(s) : Tegafur,Gimeracil

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Based on the positive opinion from EMA, Teysuno (Tegafur) an oral fluoropyrimidine will be indicated in adults for the treatment of advanced gastric cancer when given in combination with cisplatin.

                          Product Name : Teysuno

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 01, 2022

                          Lead Product(s) : Tegafur,Gimeracil,Oteracil

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : The supplemental application for approval for Opdivo® has been filed based on the data from the following 2 clinical studies: CheckMate -649 study (ONO-4538-44) and ATTRACTION-4 study (ONO-4538-37.

                          Product Name : Opdivo

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          October 12, 2020

                          Lead Product(s) : Nivolumab,Oxaliplatin,Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 28, 2019

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Taipei Veterans General Hospital | National Taiwan University Hospital | Chang Gung Memorial Hospital | National Cheng-Kung University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 07, 2018

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Chang Gung Memorial Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          National Taiwan University Hospital

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          National Taiwan University Hospital

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 20, 2017

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : TTY BIOPHARM CO LTD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Fudan University

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Fudan University

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Study Phase : Phase III

                          Sponsor : Anhui Provincial Hospital | The First Affiliated Hospital of Anhui Medical University | Anqing Municipal Hospital | Yuebei People’s Hospital | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangdong Provincial Hospital of Traditio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 13, 2016

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Anhui Provincial Hospital | The First Affiliated Hospital of Anhui Medical University | Anqing Municipal Hospital | Yuebei People’s Hospital | The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangdong Provincial Hospital of Traditio

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIO-Studien-gGmbH

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          AIO-Studien-gGmbH

                          Country arrow
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 30, 2015

                          Lead Product(s) : Tegafur

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Nordic Pharma | Taiho Pharmaceutical

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank